| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530397000 | Glycoprotein hormones | 26 |
| 20080287659 | G-CSF Conjugates - Physiologically active PEG-GCSF conjugates having a formula as follows: | 11-20-2008 |
| 20100137565 | GENETICALLY MODIFIED YEASTS FOR THE PRODUCTION OF HOMOGENOUS GLYCOPROTEINS - The present application relates to genetically modified yeasts for the production of glycoproteins having optimized and homogeneous glycan structures. These yeasts comprise an inactivation of the Och 1 gene, the integration by homologous recombination, into an auxotrophic marker, of an expression cassette comprising a first promoter, and an open reading frame comprising the coding sequence for an α-1,2-mannosidase I, and the integration of a cassette comprising a second promoter different from said first promoter and the coding sequence for an exogenous glycoprotein. These yeasts make it possible to produce EPO with an optimized and 98% homogeneous glycosylation. | 06-03-2010 |
| 20110054152 | Hydroxyalkyl Starch Derivatives - The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R′NH—R″ (II) wherein R | 03-03-2011 |
| 20110065903 | Chromatographic methods - The current invention comprises a method for the regeneration of a cation exchange chromatography column. | 03-17-2011 |
| 20110098451 | PEPTIDE-POLYMER CONJUGATES - This invention relates to a conjugate of a polymer moiety and an erythropoietin moiety. | 04-28-2011 |
| 20110098452 | PURIFICATION OF MODIFIED CYTOKINES - The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition. | 04-28-2011 |
| 20110105734 | METHOD FOR PRODUCTION OF HUMAN ERYTHROPOIETIN - Disclosed is a method for production of human erythropoietin. By the method, the cells are cultured in a serum-free medium with repetitive medium exchanges, in which medium exchange is carried out either by collecting 80 to 95% of the culture when viable cell density has reached at 2×10 | 05-05-2011 |
| 20110105735 | METHODS OF PRODUCING AND PURIFYING PROTEINS - Methods of producing and purifying proteins that comprise a glycan tag are provided. In some embodiments, a protein may be modified to include a glycan tag so as to facilitate production of the protein, e.g., by promoting protein secretion and/or promoting protein solubility. In some embodiments, the present disclosure provides methods wherein a protein may be modified to include a glycan tag, which may then be used as an affinity tag for purification. | 05-05-2011 |
| 20110118448 | Purification of pegylated polypeptides - The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGylated erythropoietin in substantially homogeneous form. | 05-19-2011 |
| 20110152506 | Method for Purifying Erythropoietin - The present invention relates to a method for preparing erythropoietin, wherein culture supernatant of erythropoietin-producing eukaryotic cells containing erythropoietin are subjected to the following steps: a) Removing the cell components; and b) treating the product from a) to the following chromatography steps in the sequence indicated i) reversed phase chromatography; ii) anion exchange chromatography; iii) hydroxyapatite chromatography. | 06-23-2011 |
| 20110275792 | METAL COORDINATED COMPOSITIONS - A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof. | 11-10-2011 |
| 20110294989 | PROCESSING OF RECOMBINANT HUMAN G-CSF - A G-CSF precursor comprising a signal peptide and a G-CSF peptide, wherein the signal peptide has the sequence of the human wild-type signal peptide of the human G-CSF/b molecule with at least one of the following mutations:
| 12-01-2011 |
| 20130253176 | HOST CELLS COMPRISING ALPHA 1, 2 MANNOSIDASE AND CULTURE METHODS THEREOF - Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided. | 09-26-2013 |
| 20140243510 | METHODS FOR PURIFYING ERYTHROPOIETIN ANALOGS HAVING LOWER ISOELECTRIC POINT - The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost. | 08-28-2014 |
| 20140309407 | Derivatisation of Erythropoietin (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 10-16-2014 |
| 20140357846 | THYROID STIMULATING HORMONE COMPOSITIONS - Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described. | 12-04-2014 |
| 20160000875 | GM-CSF FOR TREATMENT OF CHRONIC ORAL MUCOSITIS - The present invention relates to compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), or homologues thereof, and its use for treatment, prevention or alleviation of oral mucositis. The composition is preferably an aqueous solution forlocaloral administration. | 01-07-2016 |
| 20160009775 | FIBULIN PROTEIN VARIANTS AND CORRESPONDING NUCLEIC ACID SEQUENCES | 01-14-2016 |
| 20160024165 | ENHANCED LIQUID FORMULATION STABILITY OF ERYTHROPOIETIN ALPHA THROUGH PURIFICATION PROCESSING - A method for purifying rHuEPO through the use of a multi-step filtration process which provides for a rHuEPO product having superior stability and shelf-life. | 01-28-2016 |
| 20160039898 | MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES - The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent. | 02-11-2016 |
| 20160101186 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. | 04-14-2016 |
| 20160120993 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. | 05-05-2016 |
| 530398000 | Gonadatropins | 4 |
| 20100113755 | ISOLATED MODIFIED HUMAN CHORIONIC GONADOTROPIN PROTEINS - Compositions and methods based on mutant Cystine Knot Growth Factors (CKGFs) comprising amino acid substitutions relative to the wild type hormone/growth factor. Mutated glycoprotein hormones, including thyroid stimulating hormone (TSH) and chorionic gonadotropin (CG) are disclosed as exemplary mutant CKGFs. Mutant TSH heterodimers and hCH heterodimers possessed modified bioactivities, including superagonist activity. Accordingly, the present invention provides methods for using mutant CKGFs, CKGF analogs, fragments, and derivatives thereof for treating or preventing diseases. Pharmaceutical and diagnostic compositions, methods of using mutant TSH heterodimers and TSH analogs with utility for treatment and prevention of metabolic and reproductive diseases are also provided. | 05-06-2010 |
| 20100174054 | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs. | 07-08-2010 |
| 20140031530 | GLYCOPROTEIN HOMONE LONG-ACTING SUPERAGONISTS - This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 01-30-2014 |
| 20150065695 | Recombinant FSH Including Alpha 2,3- and Alpha 2,6-Sialylation - Preparations including recombinant FSH (rFSH). | 03-05-2015 |
